| Chemical Properties | Back Directory | [density ]
1.34±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:100.0(Max Conc. mg/mL);174.5(Max Conc. mM) | [form ]
A solid | [pka]
13.13±0.20(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
CB-6644 is a selective inhibitor of RUVBL1/2 complex with anti-cancer activity. CB-6644 blocks the ATPase activity of RUVBL1/2 with an IC50 of 15 nM[1]. | [Biological Activity]
CB-6644 is a selective RUVBL1/2 complex inhibitor. It inhibits the ATPase activity of RUVBL1/2 with IC50 of 15 nM; it also has anticancer activity. | [in vitro]
CB-6644 (20 μM) interacts with the RUVBL1/2 complex in Ramos cells.
CB-6644 (0.001-10 μM; 72 hours) potently kills 123 cell lines (including HCT116, NCI -1975, and HT29 cells) with an EC 50 range of 41 to 785 nM.
Cell Viability Assay | Cell Line: | 123 cell lines such as HCT116, NCI-1975, and HT29 cells | | Concentration: | 0.001, 0.01, 0.1, 1, and 10 μM | | Incubation Time: | 72 hours | | Result: | Potently killed cells with an EC 50 range of 41 to 785 nM. | | [in vivo]
CB-6644 (150 mg/kg, oral administration, 10 days of treatment for SCID-beige mice bearing Ramos xenograft models, 30 days of treatment for SCID-beige mice bearing RPMI8226 xenograft models) has antitumor activity in xenograft tumor models with tumor growth inhibitions (TGIs) of 68 and 81%, respectively in Ramos xenograft models and RPMI8226 xenograft models. | Animal Model: | SCID-beige mice bearing human tumor xenografts derived from either Burkitt's lymphoma (Ramos) or multiple myeloma (RPMI8226) cell lines | | Dosage: < /td> | 150 mg/kg | | Administration: | Oral gavage once (qd) or twice (BID) daily, 10 days of treatment for Ramos, 30 days of treatment for RPMI8226 | | Result: | There was no significant bodyweight loss in mice. TGI of 68 and 81% in Ramos and RPMI8226, respectively. | | [storage]
Store at -20°C | [References]
[1] Assimon VA, et al. CB-6644 Is a Selective Inhibitor of the RUVBL1/2 Complex with Anticancer Activity. ACS Chem Biol. 2019 Feb 15;14(2):236-244. DOI:10.1021/acschembio.8b00904 |
|
| Company Name: |
Nextpeptide Inc
|
| Telephone: |
+86-0571-81612335 +8613336028439 |
| Website: |
http://www.nextpeptide.com/ |
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|